Three-Year Follow-up of a Randomized Controlled Trial of Cognitive Therapy for the Prevention of Psychosis in People at Ultrahigh Risk

Department of Psychology, University of Manchester, Coupland Street, Manchester M13 9PL, UK.
Schizophrenia Bulletin (Impact Factor: 8.45). 06/2007; 33(3):682-7. DOI: 10.1093/schbul/sbl042
Source: PubMed


There have been recent advances in the ability to identify people at high risk of developing psychosis. This has led to interest
in the possibility of preventing the development of psychosis. A randomized controlled trial compared cognitive therapy (CT)
over 6 months with monthly monitoring in 58 patients meeting criteria for ultrahigh risk of developing a first episode of
psychosis. Participants were followed up over a 3-year period. Logistic regression demonstrated that CT significantly reduced
likelihood of being prescribed antipsychotic medication over a 3-year period, but it did not affect transition to psychosis
defined using the Positive and Negative Syndrome Scale (PANSS) or probable Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis. However, exploratory analyses revealed that CT significantly reduced the likelihood of making progression to psychosis
as defined on the PANSS over 3 years after controlling for baseline cognitive factors. Follow-up rate at 3 years was 47%.
There appear to be enduring benefits of CT over the long term, suggesting that it is an efficacious intervention for people
at high risk of developing psychosis.

Download full-text


Available from: Paul French
  • Source
    • "Psychological interventions (PSY) Study Country Design Inclusion and exclusion criteria Sample size Sample characteristics Intervention Control group Follow-up (months after baseline); drop-out rate (post-therapy) Extracted outcome; side effects Morrison et al., 2004 [75], 2007 [76]; GE 1 À UK RCT Inclusion criteria: risk for psychosis (PANSS), UHR Exclusion criteria: <16 years, >36 years; current or past receipt of "
    [Show abstract] [Hide abstract]
    ABSTRACT: This guidance paper from the European Psychiatric Association (EPA) aims to provide evidence-based recommendations on early intervention in clinical high risk (CHR) states of psychosis, assessed according to the EPA guidance on early detection. The recommendations were derived from a meta-analysis of current empirical evidence on the efficacy of psychological and pharmacological interventions in CHR samples. Eligible studies had to investigate conversion rate and/or functioning as a treatment outcome in CHR patients defined by the ultra-high risk and/or basic symptom criteria. Besides analyses on treatment effects on conversion rate and functional outcome, age and type of intervention were examined as potential moderators. Based on data from 15 studies (n=1394), early intervention generally produced significantly reduced conversion rates at 6- to 48-month follow-up compared to control conditions. However, early intervention failed to achieve significantly greater functional improvements because both early intervention and control conditions produced similar positive effects. With regard to the type of intervention, both psychological and pharmacological interventions produced significant effects on conversion rates, but not on functional outcome relative to the control conditions. Early intervention in youth samples was generally less effective than in predominantly adult samples. Seven evidence-based recommendations for early intervention in CHR samples could have been formulated, although more studies are needed to investigate the specificity of treatment effects and potential age effects in order to tailor interventions to the individual treatment needs and risk status. Copyright © 2015 Elsevier Masson SAS. All rights reserved.
    Full-text · Article · Mar 2015 · European Psychiatry
  • Source
    • "After the end of the intervention however, general transition rates increased and then almost equalled that of the group without intervention; see [49-53]. There were however, as stated above, enduring effects of CBT in that the likelihood of being prescribed antipsychotics in the three-year follow-up was reduced ([50]). Interestingly, in the group of subjects with psychological vulnerabilities targeted by the intervention, the transition risk to psychosis was also significantly reduced [49,50]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Bipolar disorders (BD) are among the most severe mental disorders with first clinical signs and symptoms frequently appearing in adolescence and early adulthood. The long latency in clinical diagnosis (and subsequent adequate treatment) adversely affects the course of disease, effectiveness of interventions and health-related quality of life, and increases the economic burden of BD. Despite uncertainties about risk constellations and symptomatology in the early stages of potentially developing BD, many adolescents and young adults seek help, and most of them suffer substantially from symptoms already leading to impairments in psychosocial functioning in school, training, at work and in their social relationships. We aimed to identify subjects at risk of developing BD and investigate the efficacy and safety of early specific cognitive-behavioural psychotherapy (CBT) in this subpopulation. Methods/Design EarlyCBT is a randomised controlled multi-centre clinical trial to evaluate the efficacy and safety of early specific CBT, including stress management and problem solving strategies, with elements of mindfulness-based therapy (MBT) versus unstructured group meetings for 14 weeks each and follow-up until week 78. Participants are recruited at seven university hospitals throughout Germany, which provide in- and outpatient care (including early recognition centres) for psychiatric patients. Subjects at high risk must be 15 to 30 years old and meet the combination of specified affective symptomatology, reduction of psychosocial functioning, and family history for (schizo)affective disorders. Primary efficacy endpoints are differences in psychosocial functioning and defined affective symptomatology at 14 weeks between groups. Secondary endpoints include the above mentioned endpoints at 7, 24, 52 and 78 weeks and the change within groups compared to baseline; perception of, reaction to and coping with stress; and conversion to full BD. Discussion To our knowledge, this is the first study to evaluate early specific CBT in subjects at high risk for BD. Structured diagnostic interviews are used to map the risk status and development of disease. With our study, the level of evidence for the treatment of those young patients will be significantly raised. Trial registration WHO International Clinical Trials Platform (ICTRP), identifier: DRKS00000444, date of registration: 16 June 2010.
    Full-text · Article · May 2014 · Trials
  • Source
    • "Furthermore, the intervention group found that CT significantly reduced the likelihood of being prescribed an antipsychotic medication and of making progression to psychosis (as defined on the Positive and Negative Syndrome Scale [PANSS] after controlling for baseline cognitive factors), after 3 years of treatment cessation. The low withdrawal rates led researchers to conclude that CT was well-tolerated by UHR individuals.82,83 "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the last few decades, substantial research has focused on the possibility of early detection and prevention of the first psychotic episode in young individuals at risk of developing this mental disturbance; however, unresolved clinical and ethical issues still call for further investigations. New perspectives and opportunities may come from the identification of selective psychopathological and instrumental markers linking the appearance of subtle psychotic symptoms with the clinical outcome of specific mental pathologies. Furthermore, empirically derived algorithms and risk staging models should facilitate the identification of targeted prevention therapies, possibly improving the efficacy of well-tolerated therapeutic approaches, such as psychological interventions and natural compound supplementations. To date, the collected evidence on the efficacy and tolerability of pharmacological prevention therapies raises more doubts than hopes. A very early detection of risk and appropriate symptomatic pattern classifications may provide a chance to better match prevention strategies with the development of psychosis.
    Full-text · Article · Mar 2014 · Therapeutics and Clinical Risk Management
Show more